Autres langues HCW Biologics Inc.

Actions

HCWB

US40423R1059

Marché Fermé - Nasdaq Autres places de cotation 22:30:01 13/05/2024			Varia. 5j.	Varia. 1 janv.
1,12 ^USD	-0,88%		-12,50%	-8,57%

01/04	HCW Biologics Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI
01/04	HCW Biologics Inc. déclare ses résultats pour le quatrième trimestre clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

HCW Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
HCW Biologics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	01/04
HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights	01/04
HCW Biologics Inc. announced that it has received $2.500005 million in funding	20/02
HCW Biologics Inc. Exercises Its Right to Terminate Its Credit Agreement	12/01
HCW Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Earnings Flash (HCWB) HCW BIOLOGICS Reports Q3 Revenue $853,102	14/11
HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights	14/11
Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting	08/11
HCW Biologics Inc. Announces Results from Preliminary Human Data Readout from an Ongoing Phase 1 Clinical Trial Sponsored by the University of Minnesota	08/11
HCW Biologics : First-in-Human Clinical Readout of HCW9218, SITC 2023	06/11
Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting	01/11
HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023	06/09/23
HCW Biologics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/08/23
Earnings Flash (HCWB) HCW BIOLOGICS Reports Q2 Revenue $622,807	11/08/23
HCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business Highlights	11/08/23
Hcw Biologics Inc. Announces Appointment of Rick S. Greene as Class II Director	14/06/23
HCW Biologics Says It Received Patent for Methods to Treat Diseases Caused by Chronic Inflammation	14/06/23
HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders	14/06/23
HCW BIOLOGICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	09/05/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues HCW Biologics Inc.

Actions

HCWB

US40423R1059

Autres langues

Filtres